Open-Label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.

Trial Profile

Open-Label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Cipargamin (Primary) ; Piperaquine
  • Indications Falciparum malaria
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Novartis Institutes for BioMedical Research
  • Most Recent Events

    • 17 Nov 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top